Sanofi reveals promising data for relapsing remitting MS treatment

pharmafile | September 20, 2016 | News story | Manufacturing and Production, Research and Development RRMS, Sanofi, relapsing remitting multiple sclerosis, relapsing-remitting multiple sclerosis 

Sanofi Genzyme, the speciality care global business unit of the French pharma firm announced six-year investigational data on Lemtrada (alemtuzumab) as a treatment for relapsing multiple sclerosis (RRMS), presenting it at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London.

Multiple sclerosis affects 100,000 people in the UK, with RRMS accounting for 85% of those cases.

Effects observed in patients treated with the drug in two Phase III studies were maintained through four additional years in an extension study, with over 90% of participants continuing. These patients were eligible to receive additional treatment with alemtuzumab if they experienced at least one relapse or at least two new or enlarging brain or spinal cord lesions.

The resulting data showed that over half the patients showed benefits of the treatment, even when their last treatment with the drug was over five years previous. At six years in the trial, 64% (225 patients) and 55% (215 patients) across the two studies did not require any additional treatments of the drug in the prior five years, with consistent effects observed across relapse, disability, brain atrophy and MRI lesion activity.  

“The Lemtrada data being presented at ECTRIMS from the ongoing extension study illustrate that more than half of patients experienced sustained effects of treatment on disease activity, despite receiving their last treatment course five years previously,” said Professor Alasdair Coles, Department of Clinical Neurosciences at the University of Cambridge. “It is very promising to see these consistent effects over time across relapse, disability and MRI measures.”

Matt Fellows

Related Content

Maze Therapeutics and Sanofi sign exclusive worldwide license agreement for Pompe disease treatment

Maze Therapeutics and Sanofi have announced that they have signed an exclusive worldwide license agreement …

Sanofi complete acquisition of mRNA company Translate Bio

French pharma giants Sanofi continues its run of acquisitions in 2021 by completing the deal …


Sanofi’s NSCLC drug gains EC approval

The European Commission (EC) has approved Sanofi and Regeneron’s PD-1 inhibitor, Libtayo (cemiplimab), for the …

Latest content